J Ethnopharmacol. 2011 Jan 27;133(2):888-96. doi: 10.1016/j.jep.2010.11.025. Epub 2010 Nov 18.
Achillea santolina L., Pistacia atlantica Desf, Rheum ribes L., Sarcopoterium spinosum (L.) Spach and Teucrium polium L. have traditionally been used as herbal antidiabetic medicines. However their alleged benefits and mechanisms remain elusive.
This study aimed to evaluate the effect of water extracts of these plants in in vitro and in vivo experiments.
In vitro enzymatic starch digestion with aqueous extracts from plants at concentrations of 1, 5, 10, 12.5, 25, 50 and 100 mg/ml was assayed using α-amylase and α-amyloglucosidase. Acarbose was used as control and glucose liberation was determined by glucose oxidase method. Oral starch tolerance test (OSTT) and oral glucose tolerance test (OGTT) were determined for the plant extracts at concentrations 125, 250 and 500 mg/kg b.wt. on Sprague-Dawley rats. Blood glucose levels in rats treated with plant extracts and drugs (acarbose or metformin and glipizide) were measured at -30, 0, 45, 90 and 135 min.
Compared to acarbose (IC(50)=1.2 μg/ml), water extracts of Pistacia atlantica, Rheum ribes and Sarcopoterium spinosum exerted significant dose dependent dual inhibition of α-amylase and α-glucosidase in in vitro enzymatic starch digestion bioassay, with IC(50)s; 46.98, 58.9 and 49.9 mg/ml, respectively. Comparable in vivo results were obtained for starch-fed rats, exhibiting significant acute postprandial antihyperglycemic efficacies. While Achillea santolina and Teucrium polium extracts lacked any favourable in vitro anti-α-amylase and anti-α-glucosidase effect, other modes of action can possibly explain their substantial acute antihyperglycemic activities in starch-treated rats. Except for Pistacia atlantica extracts, none of the investigated extracts qualified for improving the glucose intolerance in fasted rats on glucose loading.
Pistacia atlantica, Rheum ribes and Sarcopoterium spinosum can be considered as potential candidates for amelioration/management of type 2 diabetes.
山艾(Achillea santolina L.)、阿月浑子(Pistacia atlantica Desf.)、大黄(Rheum ribes L.)、刺果甘草(Sarcopoterium spinosum (L.) Spach)和牛膝草(Teucrium polium L.)传统上被用作草药抗糖尿病药物。然而,它们的益处和机制仍不清楚。
本研究旨在评估这些植物的水提取物在体外和体内实验中的作用。
使用浓度为 1、5、10、12.5、25、50 和 100 mg/ml 的植物水提取物,通过α-淀粉酶和α-葡糖苷酶测定体外酶促淀粉消化。阿卡波糖用作对照,通过葡萄糖氧化酶法测定葡萄糖释放。在 Sprague-Dawley 大鼠上,以 125、250 和 500 mg/kg bw 的浓度测定植物提取物的口服淀粉耐量试验(OSTT)和口服葡萄糖耐量试验(OGTT)。用植物提取物和药物(阿卡波糖或二甲双胍和格列吡嗪)治疗的大鼠的血糖水平在-30、0、45、90 和 135 min 时进行测量。
与阿卡波糖(IC50=1.2 μg/ml)相比,水提取物的阿月浑子、大黄和刺果甘草对体外酶促淀粉消化生物测定中的α-淀粉酶和α-葡萄糖苷酶具有显著的剂量依赖性双重抑制作用,IC50 分别为 46.98、58.9 和 49.9 mg/ml。淀粉喂养大鼠的体内结果相当,表现出显著的急性餐后降血糖作用。虽然山艾和牛膝草提取物在体外缺乏任何有利的抗α-淀粉酶和抗α-葡萄糖苷酶作用,但其他作用方式可能可以解释它们在淀粉处理大鼠中显著的急性降血糖活性。除了阿月浑子提取物外,没有一种被研究的提取物可改善禁食大鼠在葡萄糖负荷下的葡萄糖不耐受。
阿月浑子、大黄和刺果甘草可被视为改善/管理 2 型糖尿病的潜在候选药物。